TrialBlood advances2023

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.

Jorge Sierra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.